science
informative
controversial
Pfizer's lung cancer drug fails to improve patient survival rates
Jun 23, 2026, 11:49 AM10
(Update: Jun 23, 2026, 11:49 AM)
science
informative
controversial
Pfizer's lung cancer drug fails to improve patient survival rates
- Pfizer's experimental drug sigvotatug vedotin did not improve survival rates in lung cancer patients compared to standard therapy.
- The drug targets integrin beta-6, prevalent in non-small cell lung cancers, and was expected to be a breakthrough treatment.
- Despite the trial failure, Pfizer remains committed to further development and ongoing studies involving the drug.
Insights
News 1 1
Reports
Opinions
Story
“
geopolitical economic economic shift strategic economic global trends data policy strategic impact insight strategic data insight data strategic strategic shift data data analysis analysis shift geopolitical shift strategic insight strategic impact strategic global global analysis shift economic economic impact impact policy economic insight trends shift geopolitical strategic analysis trends data data geopolitical global economic shift economic data market impact strategic strategic policy trends geopolitical market insight geopolitical shift geopolitical global geopolitical insight strategic insight trends shift trends market economic data...
2026 All rights reserved
2026 All rights reserved